Biotinylated Human VEGF165 Protein, epitope tag free, ultra sensitivity, primary amine labeling (MALS verified)
分子别名（Synonym）
RP1-261G23.1, MGC70609, MVCD1, VEGFA, VPF
表达区间及表达系统（Source）
Biotinylated Human VEGF165, epitope tag free, primary amine labeling (VE5-H8210) is expressed from human 293 cells (HEK293). It contains AA Ala 27 - Arg 191 (Accession # P15692-4).
Predicted N-terminus: Ala 27
蛋白结构（Molecular Characterization）
This protein carries no "tag".
The protein has a calculated MW of 19.2 kDa. The protein migrates as 25-28 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
The protein is designed as a dimer.
标记（Labeling）
The primary amines in the side chains of lysine residues and the N-terminus of the protein are conjugated with biotins using standard chemical labeling method. A standard biotin reagent (13.5 angstroms) is used in this product.
蛋白标记度（Protein Ratio）
Passed as determined by the HABA assay / binding ELISA.
纯度（Purity）
>90% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
制剂（Formulation）
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重构方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存储（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 24 months in lyophilized state;
-70°C for 24 months under sterile conditions after reconstitution.
背景介绍
VEGF165是血管内皮生长因子A（VEGF-A）最主要的剪切变体。该蛋白由内皮细胞、巨噬细胞和T细胞等多种细胞产生，参与血管生成、血管内皮细胞存活、生长、迁移及血管通透性调节过程。VEGF基因表达受低氧条件、炎症细胞因子和癌基因诱导调控。VEGF165可与硫酸乙酰肝素结合，锚定于细胞表面及细胞外基质中。
VEGF165能与酪氨酸激酶受体VEGFR1和VEGFR2结合，且是唯一能与协同受体神经纤毛蛋白-1（NRP-1）和神经纤毛蛋白-2（NRP-2）结合的剪切变体，这些协同受体可增强VEGFR2信号传导。VEGF165与VEGFR1和VEGFR2的结合会激活PI3K/AKT、p38 MAPK、黏着斑激酶（FAK）和桩蛋白等信号通路。在多种癌症中，VEGF165通过促进肿瘤血管生成发挥关键作用。
关键字： VEGF165;VEGF165蛋白;VEGF165重组蛋白;ACRO;百普赛斯;
百普赛斯集团ACROBiosystems Group（股票代码：301080）是成立于2010年的跨国生物科技公司，是为全球生物医药、健康产业领域提供关键生物试剂产品及解决方案的行业平台型基石企业。2021年在创业板上市。百普赛斯集团业务遍布全球，横跨亚洲、北美洲、欧洲，在中国、美国、瑞士等12个城市设有办公室、研发中心及生产基地。目前累计服务客户超6000家，与全球Top 20医药企业均建立了长期、稳定的合作伙伴关系。集团旗下拥有品牌ACROBiosystems百普赛斯、bioSeedin柏思荟、Condense Capital垦拓资本和ACRODiagnostics百斯医学等。